Andrew P. Weng

15.4k citations

100 papers · 9.0k indexed · 4 hit papers · h-index 32

Hematology top 0.5%
- Acute Myeloid Leukemia Research 15
Genetics top 1%
- Chronic Lymphocytic Leukemia Research 9
Molecular Biology top 1%
- Epigenetics and DNA Methylation 16
- Cancer-related gene regulation 12
- Single-cell and spatial transcriptomics 8
Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment 28
Cancer Research top 1%
Public Health, Environmental and Occupational Health
- Acute Lymphoblastic Leukemia research 20
Immunology
- T-cell and Retrovirus Studies 8

Co-authors: Jon C. Aster Stephen C. Blacklow Adolfo A. Ferrando A. Thomas Look Cheryll Sanchez-Irizarry Lewis B. Silverman John P. Morris Woojoong Lee
Cited by: Hematology Genetics Molecular Biology
Journals: Science (1 paper)Proceedings of the National Academy of Sciences (2 papers)Journal of Biological Chemistry (2 papers)
Partner nations: Canada United States France

In The Last Decade

Andrew P. Weng

95 papers receiving 8.8k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2006 Proceedings of the National Academy of Sciences
2006 Genes & Development
2004 Science
2002 Nature Medicine

Peers

Countries citing papers authored by Andrew P. Weng

Since Specialization

Citations

This map shows the geographic impact of Andrew P. Weng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew P. Weng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew P. Weng more than expected).

Fields of papers citing papers by Andrew P. Weng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew P. Weng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew P. Weng. The network helps show where Andrew P. Weng may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Andrew P. Weng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Andrew P. Weng Line = papers co-authored together Andrew P. Weng links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Lymphocytic Variant Hypereosinophilic Syndrome: Case Series From a Tertiary Referral Center in Canada eJHaem ·Xiu Q. Wang,Kevin E. Shopsowitz,Jack Lofroth,Xuehai Wang,Erica A. Peterson,Andrew P. Weng,Luke Y. C. Chen	2025	2
2	MAGIC‐DR: An interpretable machine‐learning guided approach for acute myeloid leukemia measurable residual disease analysis Cytometry Part B Clinical Cytometry ·Kevin E. Shopsowitz,Jack Lofroth,Geoffrey Chan,Jubin Kim,Makhan Rana,Ryan R. Brinkman,Andrew P. Weng,N N Medvedev,Xuehai Wang	2024	6
3	Modeling of Li-ion Battery Thermal Runaway: Insights into Modeling and Prediction The Electrochemical Society Interface ·Paul T. Coman,Andrew P. Weng,Jason K. Ostanek,Eric Darcy,Donal P. Finegan,Ralph E. White	2024	4
4	Tcf1 is essential for initiation of oncogenic Notch1-driven chromatin topology in T-ALL Blood ·Mateusz Antoszewski,Nadine Fournier,Gustavo A. Ruiz Buendía,João Lourenço,Yuanlong Liu,Tara Sugrue,Christelle Dubey,Marianne Nkosi,Colin E.J. Pritchard,Ivo J. Huijbers,Gabriela C. Segat,Sandra Alonso-Moreno,Elisabeth Serracanta,Laura Belver,Adolfo A. Ferrando,Giovanni Ciriello,Andrew P. Weng,Ute Koch,Freddy Radtke	2022	9
5	Immune Profiling of Diagnostic DLBCL Biopsies Dramatically Improves upon Cell-of-Origin Risk Stratification Blood ·Michael Nissen,Xuehai Wang,Clémentine Sarkozy,Aixiang Jiang,Daisuke Ennishi,Tomohiro Aoki,Stacy Hung,Elizabeth A. Chavez,Jeffrey W. Craig,Pedro Farinha,Graham W. Slack,David W. Scott,Christian Steidl,Andrew P. Weng	2021	0
6	MYC-induced human acute myeloid leukemia requires a continuing IL-3/GM-CSF costimulus Blood ·Elizabeth Bulaeva,Davide Pellacani,Naoto Nakamichi,Colin A. Hammond,Philip Beer,Alireza Lorzadeh,Michelle Moksa,Annaïck Carles,Misha Bilenky,Sylvain Lefort,Jeremy Shu,Brian T. Wilhelm,Andrew P. Weng,Martin Hirst,Connie J. Eaves	2020	18
7	RUNX1 promotes cell growth in human T-cell acute lymphoblastic leukemia by transcriptional regulation of key target genes Experimental Hematology ·Catherine E. Jenkins,Samuel Gusscott,Rachel Wong,Olena O Shevchuk,Gurneet Rana,Vincenzo Giambra,Kateryna Tyshchenko,Rashedul Islam,Martin Hirst,Andrew P. Weng	2018	4
8	Epigenetic Restoration of Fetal-like IGF1 Signaling Inhibits Leukemia Stem Cell Activity Cell stem cell ·Vincenzo Giambra,Samuel Gusscott,Deanne Gracias,Raymond Song,Sonya H.L. Lam,Patrizio Panelli,Kateryna Tyshchenko,Catherine E. Jenkins,Catherine Hoofd,Alireza Lorzadeh,Annaïck Carles,Martin Hirst,Connie J. Eaves,Andrew P. Weng	2018	17
9	Inactivation of the Kinase Domain of CDK10 Prevents Tumor Growth in a Preclinical Model of Colorectal Cancer, and Is Accompanied by Downregulation of Bcl-2 Molecular Cancer Therapeutics ·Louis‐Bastien Weiswald,Mohammad R. Hasan,John C.T. Wong,Clarissa C. Pasiliao,Mahbuba Rahman,Jianhua Ren,Yaling Yin,Samuel Gusscott,Sophie Vacher,Andrew P. Weng,Hagen F. Kennecke,Ivan Bièche,David F. Schaeffer,Donald T. Yapp,Isabella T. Tai	2017	17
10	Stability of patient-specific features of altered DNA replication timing in xenografts of primary human acute lymphoblastic leukemia Experimental Hematology ·Takayo Sasaki,Juan Carlos Rivera‐Mulia,Daniel L. Vera,Jared Zimmerman,Sunny Das,Michelle R. Padget,Naoto Nakamichi,Bill H. Chang,Jeff Tyner,Brian Druker,Andrew P. Weng,Curt I. Civin,Connie J. Eaves,David M. Gilbert	2017	21
11	Focused chemical genomics using zebrafish xenotransplantation as a pre-clinical therapeutic platform for T-cell acute lymphoblastic leukemia Haematologica ·Victoria L. Bentley,Chansey J. Veinotte,Dale Corkery,Jordan Pinder,Marissa A. LeBlanc,Karen Bedard,Andrew P. Weng,Jason N. Berman,Graham Dellaire	2014	83
12	IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein Experimental Hematology ·Catherine E. Jenkins,Olena O Shevchuk,Vincenzo Giambra,Sonya H.L. Lam,Joan M. Carboni,Marco M. Gottardis,Martin Holzenberger,Michaël Pollak,R. Keith Humphries,Andrew P. Weng	2012	17
13	NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growthbreakdown → Proceedings of the National Academy of Sciences ·Teresa Palomero,Wei Keat Lim,Duncan T. Odom,Maria Luisa Sulis,Pedro J. Real,Adam A. Margolin,Kelly Barnes,Jennifer O’Neil,Donna Neuberg,Andrew P. Weng,Jon C. Aster,François Sigaux,Jean Soulier,A. Thomas Look,Richard A. Young,Andrea Califano,Adolfo A. Ferrando	2006	639
14	Mastermind critically regulates Notch-mediated lymphoid cell fate decisions Blood ·Ivan Maillard,Andrew P. Weng,Andrea C. Carpenter,Carlos G. Rodríguez,Hong Sai,Lanwei Xu,David Allman,Jon C. Aster,Warren S. Pear	2004	235
15	Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemiabreakdown → Science ·Andrew P. Weng,Adolfo A. Ferrando,Woojoong Lee,John P. Morris,Lewis B. Silverman,Cheryll Sanchez-Irizarry,Stephen C. Blacklow,A. Thomas Look,Jon C. Aster	2004	2013
16	Notch Subunit Heterodimerization and Prevention of Ligand-Independent Proteolytic Activation Depend, Respectively, on a Novel Domain and the LNR Repeats Molecular and Cellular Biology ·Cheryll Sanchez-Irizarry,Andrea C. Carpenter,Andrew P. Weng,Warren S. Pear,Jon C. Aster,Stephen C. Blacklow	2004	163
17	Modified Magrath Regimens for Adults with Burkitt and Burkitt-Like Lymphomas: Preserved Efficacy with Decreased Toxicity Leukemia & lymphoma ·Ann S. LaCasce,O. M. Zack Howard,S Li,David C. Fisher,Andrew P. Weng,Donna Neuberg,Margaret A. Shipp	2003	83
18	No T without D3 Cancer Cell ·Andrew P. Weng,Jon C. Aster	2003	6
19	Deltex1 Redirects Lymphoid Progenitors to the B Cell Lineage by Antagonizing Notch1 Immunity ·David J. Izon,Jon C. Aster,Yiping He,Andrew P. Weng,Fredrick G. Karnell,Vytas Patriub,Lanwei Xu,Sonia Bakkour,Carlos E. Rodríguez,David Allman,Warren S. Pear	2002	211
20	The Bulk Chromatin Structure of a Murine Transgene Does Not Vary with Its Transcriptional or DNA Methylation Status Molecular and Cellular Biology ·Andrew P. Weng,Peter Engler,Ursula Storb	1995	15

About Andrew P. Weng

Andrew P. Weng is a scholar working on Hematology, Pathology and Forensic Medicine and Immunology, having authored 100 papers that have together received 9.0k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (28 papers), Acute Lymphoblastic Leukemia research (20 papers), Epigenetics and DNA Methylation (16 papers), Acute Myeloid Leukemia Research (15 papers), Cancer-related gene regulation (12 papers), Chronic Lymphocytic Leukemia Research (9 papers), T-cell and Retrovirus Studies (8 papers) and Single-cell and spatial transcriptomics (8 papers). The work is most often cited by research in Hematology (1.4k citations), Genetics (924 citations) and Molecular Biology (5.7k citations). Andrew P. Weng has collaborated with scholars based in Canada, United States and France. Frequent co-authors include Jon C. Aster, Stephen C. Blacklow, Adolfo A. Ferrando, A. Thomas Look, Cheryll Sanchez-Irizarry, Lewis B. Silverman, John P. Morris, Woojoong Lee, Warren S. Pear and Donna Neuberg. Their work appears in journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact